Cita APA

Mooradian, M. J., Reuben, A., Prieto, P. A., Hazar-Rethinam, M., Frederick, D. T., Nadres, B., . . . Sullivan, R. J. (2018). A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma. Oncoimmunology.

Citación estilo Chicago

Mooradian, Meghan J., et al. "A Phase II Study of Combined Therapy With a BRAF Inhibitor (vemurafenib) and Interleukin-2 (aldesleukin) in Patients With Metastatic Melanoma." Oncoimmunology 2018.

Cita MLA

Mooradian, Meghan J., et al. "A Phase II Study of Combined Therapy With a BRAF Inhibitor (vemurafenib) and Interleukin-2 (aldesleukin) in Patients With Metastatic Melanoma." Oncoimmunology 2018.